A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients

References

• Kulik L , El-Serag HB . Epidemiology and management of hepatocellular carcinoma. Gastroenterology . 2019;156(2):477–491 e471. doi:10.1053/j.gastro.2018.08.065 30367835
   PubMed Web of Science ®Google Scholar
• Llovet JM , Zucman-Rossi J , Pikarsky E , et al. Hepatocellular carcinoma. Nat Rev Dis Primers . 2016:216018. doi:10.1038/nrdp.2016.18
   Web of Science ®Google Scholar
• Sherman M . Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol . 2014;28(5):783–793. doi:10.1016/j.bpg.2014.08.008 25260308
   PubMed Web of Science ®Google Scholar
• Croswell JM , Ransohoff DF , Kramer BS . Principles of cancer screening: lessons from history and study design issues. Semin Oncol . 2010;37(3):202–215. doi:10.1053/j.seminoncol.2010.05.006 20709205
   PubMed Web of Science ®Google Scholar
• Zhang BH , Yang BH , Tang ZY . Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol . 2004;130(7):417–422. doi:10.1007/s00432-004-0552-0 15042359
   PubMed Web of Science ®Google Scholar
• Degasperi E , Colombo M , Doyle A , Gorgen A , Muaddi H . Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol . 2018;18(1):156–164. doi:10.1016/S2468-1253(16)30018-8
   Web of Science ®Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O . EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol . 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004 27062661
   PubMed Web of Science ®Google Scholar
• Hsu CY , Liu PH , Ho SY , et al. Using nomogram of the barcelona clinic liver cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer . 2018;18(1):289. doi:10.1186/s12885-018-4202-3 29540157
   PubMed Web of Science ®Google Scholar
• Teng TZJ , Shelat VG . Testosterone gel improves appetite and reduces tiredness in males with advanced cancer. BMJ Support Palliat Care . 2021;11(2):145. doi:10.1136/bmjspcare-2020-002662
   PubMed Web of Science ®Google Scholar
• Zhou Y . Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients. Int J Clin Exp Pathol . 2018;11(10):4867–4878.31949562
   PubMed Web of Science ®Google Scholar
• Liu YS , Lin CY , Chuang MT , et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol . 2018;18(1):124. doi:10.1186/s12876-018-0848-1 30075752
   PubMed Web of Science ®Google Scholar
• Doyle A , Gorgen A , Muaddi H , et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3cm in potentially transplantable patients. J Hepatol . 2019;70(5):866–873. doi:10.1016/j.jhep.2018.12.027 30615906
   PubMed Web of Science ®Google Scholar
• Uhlig J , Sellers CM , Stein SM , Kim HS . Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States national cancer database. Eur Radiol . 2019;29(5):2679–2689. doi:10.1007/s00330-018-5902-4 30560364
   PubMed Web of Science ®Google Scholar
• Gui CH , Baey S , D’Cruz RT , Shelat VG . Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - a meta-analysis. Eur J Surg Oncol . 2020;46(5):763–771. doi:10.1016/j.ejso.2020.01.004 31937433
   PubMed Web of Science ®Google Scholar
• Lei GY , Junnarkar LS , Huey T , Shelat V . Predictors of 90-day mortality following hepatic resection for hepatocellular carcinoma. Visc Med . 2020. doi:10.1159/000510811
   Web of Science ®Google Scholar
• Zhang L , Ge NL , Chen Y , et al. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients. Med Oncol . 2015;32(3):77. doi:10.1007/s12032-015-0532-z 25698535
   PubMed Web of Science ®Google Scholar
• Cosgrove DP , Reyes DK , Pawlik TM , Feng AL , Kamel IR , Geschwind JF . Open-label single-arm phase II trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: clinical results. Radiology . 2015;277(2):594–603. doi:10.1148/radiol.2015142481 26069923
   PubMed Web of Science ®Google Scholar
• Kloeckner R , Weinmann A , Prinz F , et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer . 2015:15465. doi:10.1186/s12885-015-1480-x
   Web of Science ®Google Scholar
• Ahmed S , de Souza NN , Qiao W , Kasai M , Keem LJ , Shelat VG . Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg . 2016;20166120143. doi:10.1155/2016/6120143
   Google Scholar
• Maeda M , Saeki I , Sakaida I , et al. Complications after radiofrequency ablation for hepatocellular carcinoma: a Multicenter Study Involving 9411 Japanese patients. Liver Cancer . 2020;9(1):50–62. doi:10.1159/000502744 32071909
   PubMed Web of Science ®Google Scholar
• Zhang ZS , Li HZ , Ma C , Xiao YD . Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. BMC Cancer . 2019;19(1):1162. doi:10.1186/s12885-019-6386-6 31783814
   PubMed Web of Science ®Google Scholar
• Chen S , Ji R , Shi X , Wang Z , Zhu D . Retrospective analysis of efficacy, safety, and prognostic factors in a cohort of Chinese hepatocellular carcinoma patients treated with drug-eluting bead transarterial chemoembolization. Braz J Med Biol Res . 2019;52(12):e8467. doi:10.1590/1414-431x20198467 31800729
   PubMed Web of Science ®Google Scholar
• Sacco R , Bargellini I , Bertini M , et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol . 2011;22(11):1545–1552. doi:10.1016/j.jvir.2011.07.002 21849247
   PubMed Web of Science ®Google Scholar
• Kang YJ , Lee BC , Kim JK , et al. Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating barcelona clinic liver cancer stage 0/A hepatocellular carcinoma. Cardiovasc Intervent Radiol . 2020;43(1):55–64. doi:10.1007/s00270-019-02349-9 31646378
   PubMed Web of Science ®Google Scholar
• Hsieh CB , Chang HM , Chen TW , et al. Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma. World J Gastroenterol . 2004;10(4):505–508. doi:10.3748/wjg.v10.i4.505 14966906
   PubMed Web of Science ®Google Scholar
• Imai N , Ishigami M , Ishizu Y , et al. Transarterial chemoembolization for hepatocellular carcinoma: a review of techniques. World J Hepatol . 2014;6(12):844–850. doi:10.4254/wjh.v6.i12.844 25544871
   PubMedGoogle Scholar